Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Molecular Factors Associated With Minimal Residual Disease in Newly Diagnosed Multiple Myeloma After Quadruplet Therapy

  • By

  • Florence Magrangeas

  • Mia Cherkaoui

  • Victor Bessonneau-Gaborit

  • Jennifer Derrien

  • Céline Chevalier

  • Catherine Guérin-Charbonnel

  • Benjamin Diamond

  • Mehmet Kemal Samur

  • Cyrille Hulin

  • Denis Caillot

  • Lionel Karlin

  • Bertrand Arnulf

  • Ola Landgren

  • Nikhil C. Munshi

  • Hervé Avet-Loiseau

  • Ludovic Martinet

  • Jill Corre

  • Aurore Perrot

  • Philippe Moreau

  • Cyrille Touzeau

  • Stéphane Minvielle

  • Eric Letouzé

  • October 19, 2026

Share

Original Source(s)

Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Ola Landgren, Nikhil C. Munshi, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle, Eric Letouzé

  • October 19, 2026

Related Content

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

  • October 15, 2026

  • 1 min
Weekly hippocampal diffusion changes during partial-brain radiation therapy for high-grade glioma: associations with dose and early memory change

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer